HEPA logoHEPA
Hepion Pharmaceuticals Inc

27,551
Loading...
Loading...
News
all
press releases
Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'
Despite a sharp decline in stock price, retail traders are optimistic about the company's potential, citing its core asset Rencofilstat and speculating on a rebound following the OTC transition.
Stocktwits·4mo ago
News Placeholder
More News
News Placeholder
Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer
Hepion Pharmaceuticals announces merger with Pharma Two B Ltd., creating a combined company focused on Parkinson's disease treatment. The merger values Hepion at $58.5 million, and Pharma Two B plans...
Benzinga·1y ago
News Placeholder
Hepion Pharmaceuticals' Strategic Merger and Corporate Restructuring
An update from Hepion Pharmaceuticals (HEPA) is now available. Hepion Pharmaceuticals has entered into a merger agreement with Pharma Two B Ltd. an...
TipRanks Financial Blog·1y ago
News Placeholder
Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?
Updates on Hepion Pharmaceuticals' ASCEND-NASH Trial, now in wind-down phase. Explore insights into Phase 2b study progression and strategic alternatives. read more...
Benzinga·1y ago
News Placeholder
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of...
Globe Newswire·2y ago
News Placeholder
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug...
Globe Newswire·2y ago
News Placeholder
Hepion Pharmaceuticals to Present at NASH-TAG 2024
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ( AI )-driven therapeutic...
Globe Newswire·2y ago

Latest HEPA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.